To understand the possible role of neutralizing monoclonal antibodies and other antiviral interventions in patients hospitalized for COVID-19, the National Institute of Health established the ACTIV-3 (Therapeutics for Inpatients with COVID-19) platform, for conducting efficient trials. CTSN has participated in designing and conducting the ACTIV-3 trials. ACTIV3/TICO is designed as a platform for simultaneous blinded placebo-controlled randomized trials of therapeutics in hospitalized COVID-19 patients, utilizing a shared control group.

Study Title Start Date End Date Sample Size
A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS from COVID-19 (MSC-COVID) Apr 2020 Dec 2021 222
Randomized Trial Evaluating an External Support Device for Saphenous Vein in CABG (VEST) Jan 2018 Feb 2020 224
Hybrid Coronary Revascularization Trial (HYBRID) Oct 2017 Mar 2021 200
Safety & Efficacy Of Intramyocardial Injection Of Mesenchymal Precursor Cells On Myocardial Function In LVAD Recipients (LVAD MPC II) May 2015 Aug 2017 159
Management Practices And The Risk Of Infections Following Cardiac Surgery (Major Infections) Mar 2015 Jul 2016 5158
Neuroprotection In Patients Undergoing Aortic Valve Replacement (Neuroprotection) Mar 2015 Jul 2016 383
Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation (POAF) May 2014 May 2015 523
LVAD Therapy: Exploring The Effect Of Intramyocardial Injection Of Mesenchymal Precursor Cells On Myocardial Function (LVAD I) May 2012 Jun 2013 30
Surgical Ablation Versus No Surgical Ablation For Patients With Persistent Or Longstanding Persistent Atrial Fibrillation Undergoing Mitral Valve Surgery (AF Ablation) Jan 2010 Oct 2014 260
Surgical Interventions For Moderate Ischemic Mitral Regurgitation (MMR) Jan 2009 Jun 2014 301
Evaluation Of Outcomes Following Mitral Valve Repair/Replacement In Severe Chronic Ischemic Mitral Regurgitation (SMR) Dec 2008 Jun 2013 251